Dubroff: Looking for answers in a 300-year-old account of a Plague Year
Nearly 300 years ago, in 1722, a businessman turned journalist named Daniel Defoe recounted the deadly outbreak of bubonic plague that brought London to its knees in 1665. His book, “A Journal of The Plague Year,” became a bestseller, and over the summer, I re-read the paperback copy I picked up during my junior year Read More →
Tourism in a pandemic: To promote, or not to promote?
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The great outdoors: Region copes with new tourism reality
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Hair: State budget sets aside $8.3 million for housing in the face of pandemic
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: Santa Barbara’s budget woes not solved with cannabis alone
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Opinion: PPP loans provide lifeline to tri-county businesses
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen puts $421M into BeiGene
Thousand Oaks biotech giant Amgen has upped its investment in Chinese oncology research firm BeiGene by $421 million. Amgen’s new investment, announced July 13, will allow the company maintain its ownership interest in BeiGene at 20.3 percent following a direct offering by the Chinese firm. Amgen shares rose more than 1 percent following the news Read More →
